220
Participants
Start Date
April 28, 2014
Primary Completion Date
August 8, 2016
Study Completion Date
August 8, 2016
Benralizumab
Benralizumab administered subcutaneously every 4 weeks
Placebo
Placebo subcutaneously on study week 0 until study week 24 inclusive.
Benralizumab
Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
Research Site, CABA
Research Site, Florida
Research Site, Samokov
Research Site, Petrich
Research Site, Vratsa
Research Site, Kozloduy
Research Site, Pazardzhik
Research Site, Mendoza
Research Site, Rousse
Research Site, Berlin
Research Site, The Bronx
Research Site, Marseille
Research Site, Pittsburgh
Research Site, Suwon
Research Site, Philadelphia
Research Site, Großhansdorf
Research Site, Vinnytsia
Research Site, Winston-Salem
Research Site, Durham
Research Site, Málaga
Research Site, Mt. Pleasant
Research Site, Brest
Research Site, Hanover
Research Site, Toulouse
Research Site, Orlando
Research Site, Hialeah
Research Site, Hialeah
Research Site, Miami
Research Site, Istanbul
Research Site, Montpellier
Research Site, Istanbul
Research Site, Fort Mitchell
Research Site, Middleburg Heights
Research Site, Cincinnati
Research Site, Valencia
Research Site, Dnipropetrovsk
Research Site, Iowa City
Research Site, Madison
Research Site, Mainz
Research Site, Rochester
Research Site, Kharkiv
Research Site, Kharkiv
Research Site, Strasbourg
Research Site, Lyon
Research Site, Oklahoma City
Research Site, Ivano-Frankivsk
Research Site, Freiburg im Breisgau
Research Site, Centennial
Research Site, Denver
Research Site, Los Angeles
Research Site, Bamberg
Research Site, Valparaíso
Research Site, Rancagua
Research Site, Talca
Research Site, Talcahuano
Research Site, Santiago
Research Site, Buenos Aires
Research Site, Calgary
Research Site, Vancouver
Research Site, Hamilton
Research Site, Ottawa
Research Site, Montreal
Research Site, Québec
Research Site, Quillota
Research Site, Bursa
Research Site, Leipzig
Research Site, Bydgoszcz
Research Site, Karczew
Research Site, Koszalin
Research Site, Krakow
Research Site, Krakow
Research Site, Lodz
Research Site, Lubin
Research Site, Szczecin
Research Site, Tarnów
Research Site, Trzebnica
Research Site, Wroclaw
Research Site, Wroclaw
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Adana
Research Site, Ankara
Research Site, Kyiv
Research Site, Kyiv
Lead Sponsor
AstraZeneca
INDUSTRY